Introduction
Given the increasing numbers of HIV-seropositive individuals with oral and oesophageal candidosis that are failing to respond to fluconazole (Fox et al., 1991; Savage & Harris, 1991; Smith et al., 1991; Bailey et al., 1993; Boken, Swindells & Rinaldi, 1993; Cartledge et al., 1993) , there is a need for susceptibility testing of each individual isolate of Candida spp. to antifungal agents so that the most effective treatment can be chosen.
Determining the minimum inhibitory concentration (MIC) of azole antifungal agents is hampered by indistinct and trailing endpoints and the methods are vulnerable to relatively minor alterations in test conditions e.g. temperature, medium composition and inoculum size (Rex et al., 1993) . In an attempt to overcome these problems, the National Committee for Clinical Laboratory Standards of the USA has produced a protocol for antifungal susceptibility tests employing doubling dilutions of the agents (NCCLS, 1992) . In the same year, Odds (1992) developed a new approach to antifungal susceptibility testing by determining the inhibition of an isolate to a single fixed concentration of the antifungal agent relative to the growth of the same isolate in drug free medium. This method is technically straightforward and allows the susceptibility of an isolate to be determined simultaneously to a wide range of antifungal agents. In a retrospective study, we were impressed by the close agreement between the MICs determined by the NCCLS method and the results of the relative growth test and also by the latter's ability to discriminate between isolates from patients whose candidosis failed to respond to fluconazole and those from patients with no history of azole failure (Cartledge et al., 1993) . We therefore undertook to evaluate prospectively the relative growth method in predicting the clinical response of a large cohort of HIV seropositive patients treated with fluconazole for oral and oesophageal candidosis.
Materials and methods

Isolates
Mouth swabs and rinses and oesophageal washings were obtained within one month of starting fluconazole therapy from patients infected with HIV attending our Candida clinic between January 1992 and December 1993. Isolates were tested for their ability to produce germ tubes in horse serum, for chlamydospore induction on Rice Tween Agar medium (bio Merieux, Basingstoke, Hampshire, UK) and identified using the API 20 C auxanogram (bio Merieux, Basingstoke, Hampshire, UK).
Preparation of the inoculum
Clinical specimens were inoculated onto Sabouraud's Dextrose agar and incubated for 48 h at 37°C. Three similar colonies were then subcultured onto pancreatic casein digest/yeast extract/glucose (CYG) agar pH 7.2 which was composed of 30 g/L yeast extract (Difco Laboratories, Detroit, MI), 30 g/L pancreatic casein digest (Merck, Darmstadt, Germany), 60 g/L glucose (BDH Laboratory Supplies, Poole, UK), 100 g/L morpholinopropanesulphonic acid (MOPS) (BDH) and 30 g/L Tris (BDH). When there were obvious differences in the colonial appearance, three subcultures of each distinct colony was made. After 48 h incubation at 37°C, the growth from each CYG plate was used to lightly inoculate three separate tubes containing 5 mL 10% CYG broth which were then incubated for 18-24 h at 30°C rotating at 20 rpm to ensure a consistent turbidity. Each broth culture was diluted 1 in 400 in sterile distilled water to prepare an inoculum of cl0 5 cfu/mL.
Determining the relative growth inhibition
For each colony of each isolate, three wells of a flat bottomed microtitration plate (ICN Biomedicals Ltd, Thame, Oxfordshire, UK) were charged with 20 fiL of 10 x concentrated CYG broth to provide the growth control and one well was charged with 20 nL of the same broth containing 3 mg/L (10~5 M) fluconazole. Each well was then filled with 200 pL of the inoculum. A negative control well was also prepared by filling a well with 20 /iL of concentrated CYG and 200/iL sterile water. The plates were sealed with acetate strips (ICN) and incubated at 37 C C for 3 days, after which the acetate strips were removed and the turbidity measured by a spectrophotometer using a 405 nm filter. The readings were corrected for background absorbance by subtracting the value of the negative control well.
Calculating the relative growth
The relative growth was calculated by dividing the optical density (OD) of the medium containing fluconazole by the mean OD of the growth controls and expressing the result as a percentage. Since each isolate was tested in triplicate, the mean of these three relative growth values was used in the analysis. All three values for each test differed by less than 20%.
Definition of resistance
Candida spp. isolated before treatment or at the time of failure from patients with clinical evidence of persistent candidosis despite 7 days' treatment with a least 100 mg/day were considered to be resistant to fluconazole. Isolates of Candida spp. from patients who responded clinically to 7 days' treatment with less than 200 mg/day fluconazole or a single dose of 400 mg fluconazole were considered susceptible.
Test performance
A true positive test and a true negative test occurred when the isolate was classified both clinically and in vitro as being resistant or susceptible respectively. An isolate that was clinically resistant but found susceptible in vitro was a false negative result and one which was clinically susceptible but resistant in vitro was a false positive result. The specificity was calculated by dividing the number of true negatives by the sum of true negatives and false positives. The sensitivity was calculated by dividing the number of true positives by the sum of true positives and false positives. These parameters were used to calculate the predictive value of the test for clinical resistance to fluconazole using different relative growth values.
A receiver operator characteristic curve (ROC) was constructed by plotting the specificity against the complement of the sensitivity to illustrate how altering the cut-off point affected the sensitivity and specificity of the test. ROC curves may be used to illustrate the degree of overlap between the test results of diseased and non-diseased populations or, as in this study, those with and without clinically significant fluconazole resistant candidosis (Henderson, 1993) . When the slope of the curve is close to 45°t hen it is concluded that the test fails to differentiate between the two populations in question. Where there is no overlap between the results of diseased and non-diseased populations, the curve becomes superimposed on the j>-axis and then runs parallel to the .v-axis where the sensitivity is 100%. In addition, the ROC curve can be used to identify the optimum cut-off point for achieving a predetermined level of sensitivity or specificity, dependent upon whether it is more important for the particular test to have a high sensitivity i.e. not miss any cases, even at the expense of a higher false positive rate or high specificity i.e. to be confident that a negative result is unlikely to be falsely negative.
Statistical analyses
Non-parametric variables such as CD4 count, the time since the diagnosis of AIDS and time since the first episode of candidosis was diagnosed were compared using the J. D. Cartledge et ai.
Mann-Whitney U tests. The Chi-squared test was used to compare the proportion of patients with AIDS in each sub-group.
Results
Patients and isolates
A specimen was obtained from each of 104 patients who received fluconazole treatment for candidosis within 1 month of sample collection. Of these, 48 were considered clinically resistant, having failed to respond to at least one week's treatment with 100 mg/day or more fluconazole (ten patients had received 100 mg/day fluconazole, 17 200 mg/day, 17 400 mg/day and 4 800 mg/day). Those individuals with clinically resistant candidosis were more markedly immunosuppressed, were more likely to have AIDS and have experienced a longer history of recurrent candidosis than those who responded to fluconazole (Table I) .
There was no relationship between relative growth indices and failed dose as median values of 94.5% (89-107%) were obtained from the yeasts isolated from patients failing 100 mg/day, 95.4% (87-104%) from those failing 200 mg/day, 98% (88-108%) from those failing 400 mg/day and 94.5% (93-100%) from those failing 800 mg/day.
A single isolate was obtained from 93 (89%) of the 104 specimens and, of the 11 that appeared to yield a mixture of isolates (Table II) , different Candida species were present in eight cases. In the remaining three cases, the isolates were retested and shown to have widely different susceptibilities to fluconazole (Table II) .
Using the ROC curve to select the cut off point
Using a series of different relative growth values to define resistance, the ROC curve became superimposed on the v-axis and ran parallel to the x-axis yielding a sensitivity approaching 100% indicating that the test differentiated well between patients with clinically resistant candidosis and those without. Consequently, we were able to select a relative growth value of 88% as a cut off point which achieved a sensitivity of 98% and specificity of 96% (Table III) .
When a low cut off point was used to define resistance in vitro, all the clinically resistant isolates were correctly classified as being resistant as were many of the clinically susceptible isolates as their relative growth exceeded the cut off point making the test less sensitive while retaining high specificity. With high cut off points the reverse was true, in that all the isolates from unresponsive patients were classified as being resistant achieving 100% specificity but the relative growths of some were less than the cut-off point giving a false negative result and therefore leading to poorer sensitivity as illustrated by the ROC curve (Figure) .
A ccuracy of the method
When the mixed yeast isolates from the specimens obtained from 11 patients were included, the accuracy of the method was diminished. Six of these patients had candidosis which responded to fluconazole clinically. If these 11 patients' specimens are excluded from the analysis, all isolates from patients failing to respond to treatment achieved a relative growth in the drug of >88% and all those from responsive patients w a. achieved relative growth of <75%. Thus, any cut-off value falling between 75% and 88% would achieve 100% for both sensitivity and specificity. Of the 56 Candida albicans isolated from patients who responded to treatment with fluconazole, all but two appeared to be fluconazole susceptible in vitro and both these isolates were found in mixed infections (Table III) . One of the two Candida glabrata was classified as resistant as was the Saccharomyces sp. However, the relative growths of the apparently susceptible C. glabrata as well as the Candida krusei were only 1-2% below the cut-off value as was the relative growth of one isolate of C. albicans from a mixed infection. Two of the C. albicans isolated from cases of clinically resistant candidosis were apparently susceptible in vitro and both were isolated from mixed infections. All 11 non-albicans Candida spp. and both Saccharomyces spp. were relatively insensitive to fluconazole and all five cases involving a single non-albicans species failed to respond clinically to fluconazole. The susceptibility of the C. albicans isolate in mixed specimens accurately predicted the clinical response of all but one of the eight patients, the susceptibility of the non-albicans yeast was only predictive of response in five cases (Table III) .
Discussion
These results confirm that Odds' technique is a sensitive and specific predictor of the response of buccal candidosis to treatment with fluconazole, particularly when infection due to mixtures of susceptible and resistant yeasts are excluded. The differences in clinical response of patients with mixed infections may reflect differences in the relative numbers of resistant and susceptible yeasts. In addition, when different Candida species were involved, the relative growth of the non-albicans Candida spp. was less helpful in predicting clinical response than was that of the C. albicans, suggesting either that the non-albicans Candida spp. is of minor clinical importance and perhaps a commensal, or that measuring the relative growth is less accurate for these yeasts.
Species other than C. albicans which could have been responsible for clinical resistance were found only in a minority of cases. In most of these instances, these species were found in conjunction with C. albicans and the clinical response appeared to depend on the susceptibility of the C. albicans rather than of the non-albicans yeasts. Saccharomyces cerevisiae is likely to be a contaminant obtained in mouth washings from food residue. Indeed, its presence in the specimens from two patients in this study did not alter the clinical outcome predicted by the susceptibility of the C. albicans which were also isolated. Whatever their pathogenic significance, non-albicans yeasts accounted for only 13 (11%) of the 115 isolates, and until a larger study is conducted to evaluate relative growths to test their susceptibility it would seem prudent to restrict the method we proposed to C. albicans.
It is always possible that the susceptibility of Candida spp. may not be uniform in every case of candidosis and that selection of less susceptible members of the population during treatment might account for the development of clinically significant resistance. By only testing three colonies from each clinical specimen to represent the yeast populations, we might have missed a resistant subpopulation. Thus it may be that if a larger sample were picked, greater variation in susceptibility might be detected and thus lead to confusion. However, we feel that testing three colonies is a reasonable compromise especially as there was agreement regarding susceptibility to fiuconazole in over 90% of cases.
Our definition of clinical resistance to fiuconazole as being failure to respond to at least 100 mg/day of the azole after 7 days, therapy appeared to have been valid since only two of the 48 patients who satisfied these criteria and from whom resistant yeasts were isolated subsequently responded to higher doses of the drug, one responding to 400 mg/day and another to 800 mg/day. The yeasts isolated from patients who failed to respond to 100 mg/day fiuconazole were no less resistant in vitro than were those recovered from patients failing treatment with higher doses. Since all but one of these patients was infected with yeasts that exhibited a high relative growth it appears likely that this does represent resistance in vitro and that this, rather than other factors such as failure to absorb the drug, accounts for treatment failure. This study was not designed to show the prevalence of candidosis due to fiuconazole resistant Candida spp. in HIV infected individuals especially as such individuals are more likely to be referred to our Candida clinic than those infected with susceptible strains. None the less, our findings suggest that fluconazole resistance is a significant problem, particularly for those with lower CD4 lymphocyte counts who tend to have a longer history of recurrent candidosis than do patients with susceptible thrush. We believe that the results obtained using this method are a valuable indication of clinically significant fluconazole resistance in patients infected with HIV who have oral candidosis. Further studies also seem warranted to evaluate Odds' test further for its potential value in assessing resistance to other antifungal compounds.
